News | March 17, 2010

Data Demonstrate Superior Performance of Drug-Eluting Stent

The CYPHER Sirolimus-eluting Coronary Stent

March 15, 2010 — Investigators reported the long-term follow-up of the largest randomized comparison between the two drug-eluting stents during the American College of Cardiology annual meeting this week in Atlanta.

The study highlighted the clinical differences between CYPHER Sirolimus-eluting Coronary Stent and Medtronic’s Endeavor Stent. The findings were also published on-line in the journal The Lancet. The CYPHER Stent was associated with significantly lower rates of death, myocardial infarction, and repeat revascularization than the Endeavor Stent out to 18 months.

The large randomized trial SORT OUT III included more than 2,300 patients across a wide range of lesion and patient complexity. The investigators reported that the mortality rate (4.4 for Endeavor vs. 2.7 percent for CYPHER), incidence of heart attacks (2.1 for Endeavor vs. 0.9 percent for CYPHER), and composite endpoint of MACE (9.7 for Endeavor vs. 4.5 percent for CYPHER) was significantly lower in patients receiving CYPHER compared to those receiving Endeavor.

The incidence of “definite” late stent thrombosis was higher for Endeavor than for CYPHER, but this difference was not statistically significant (1.1 for Endeavor vs. 0.5 percent for CYPHER). Coupled with the safety advantage observed with CYPHER, there was an efficacy advantage as well: CYPHER had significantly less frequent ischemia-driven target lesion revascularization through 18 months compared to Endeavor (1.7 for CYPHER vs. 6.1 percent Endeavor).

“The SORT OUT III data highlight the excellent long-term safety and efficacy data of the CYPHER Stent in a broad range of patients, and further show that there are important safety and efficacy differences between drug-eluting stents, in this case the CYPHER Stent and the Endeavor Stent,” said Campbell Rogers, M.D., chief scientific officer and head of global research and development for Cordis Corp.

There now have been six different sets of data from randomized clinical trials and registries — Endeavor III, SORT OUT III, ZEST, ISAR TEST II, the SCAAR diabetes data and the Western Denmark Registry — in which the CYPHER Stent outperformed the Endeavor Stent in key outcome measures, including in long term follow-up,” Dr. Rogers said.

The safety and efficacy of the device is supported by a robust clinical trial program that includes more than 70 studies that examine the performance of the CYPHER Stent in a broad range of patients.

For more information: www.cypherstent.com

Related Content

New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...
A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
Overlay Init